TMFEBCapital

Todd Campbell

TMFEBCapital’s Activity

Today

NL

Article

EBCapitalMarkets published an article 3:59 PM

Earnings Roundup: Did Obamacare Swamp United Healthcare's Quarter?

Medicaid membership surged at United Healthcare (UNH) in Q1, offsetting headwinds tied to Obamacare fees and higher taxes, and suggesting strong results for Medicaid insurers Molina (MOH) and Centene (CNC).

NL

Article

EBCapitalMarkets published an article 11:43 AM

Earnings Roundup: St. Jude's 1 Bright Spot

St Jude's (STJ) electrophysiology business is the one bright spot in an otherwise dim earnings report.

Yesterday

NL

Article

EBCapitalMarkets published an article 11:02 AM

3 Reasons Rite Aid Continues to Crush the Market

Shares in Rite Aid (RAD) may keep heading higher thanks to these three reasons.

NL

Article

EBCapitalMarkets published an article 10:28 AM

Earnings Roundup: Johnson & Johnson Results Are Better Than They Appear

Slow growth from medical device and consumer goods masked robust sales in Johnson & Johnson's drug business.

Tue Apr 15

NL

Article

EBCapitalMarkets published an article 5:29 PM

Down 17%: Is Isis Pharmaceuticals Worth Buying Now?

Despite a deep product pipeline of intriguing RNAi drugs, shares in Isis (ISIS) have toppled this year. Here's what you need to know about Isis and the catalysts likely to move its shares in the coming year.

NL

Article

EBCapitalMarkets published an article 4:55 PM

Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.

Here's what you need to know about Amgen (AMGN) and Biogen's (BIIB) upcoming first quarter earnings report.

NL

Article

EBCapitalMarkets published an article 1:58 PM

Earnings Primer: What's on Deck for Celgene, AbbVie, and Gilead

Here's what you need to know about Celgene (CELG), AbbVie (ABBV), and Gilead (GILD) before they report their first quarter earnings later this month.

NL

Article

EBCapitalMarkets published an article 1:02 PM

Earnings Roundup: Rite Aid Impresses

Here's what you need to know about Rite Aid's recent earnings and its plans to challenge market share leaders CVS and Walgreen.

Mon Apr 14

NL

Article

EBCapitalMarkets published an article 1:06 PM

1 Stock Helping Revolutionize Diabetes Monitoring

New products in development with partners Johnson & Johnson and Tandem could help Dexcom outmaneuver its chief competitor, Medtronic.

Sun Apr 13

NL

Article

EBCapitalMarkets published an article 8:17 PM

Better Buy: Illumina, Inc. Vs. Intuitive Surgical, Inc.

Investors have bid up shares in Illumina (ILMN) and Intuitive Surgical (ISRG) to frothy levels in the past. With markets off their highs, is one a better buy than the other?

Fri Apr 11

NL

Article

EBCapitalMarkets published an article 3:20 PM

Impax Breathes New Life Into Stalled Parkinson's Drug

Impax's (IPXL) stumbles in bringing Rytary, it's long lasting Parkinson's drug, to market may finally be over given its re-filed with the FDA for approval.

NL

Article

EBCapitalMarkets published an article 10:37 AM

2 Ways To Invest in This 1 Big Spending Trend

Double digit growth in the largest category for drug spending may support Sanofi (SNY) and Merck (MRK) through 2016.

Thu Apr 10

NL

Article

EBCapitalMarkets published an article 6:57 PM

Are Celgene and Amgen Undervalued By the Market?

Celgene (CELG) and Amgen (AMGN) shares have fallen as investors have shifted away from biotech, but that may not mean they're cheap yet.

NL

Article

EBCapitalMarkets published an article 1:28 PM

Merck Shouts "Me, Too!" But Will It Matter?

Merck (MRK) joins Gilead (GILD), Bristol-Myers (BMY), and AbbVie (ABBV) in the race to cure hepatitis C, but Merck may end up trailing the pack.

NL

Article

EBCapitalMarkets published an article 9:30 AM

3 Breast Cancer Drugs With Big Potential

CDK 4/6 Inhibitor breast cancer drugs from Pfizer (PFE), Novartis (NVS), and Lilly (LLY) are making their way through trials and may soon give patients and doctors a new, important weapon in HER2 positive breast cancer.

Wed Apr 9

NL

Article

EBCapitalMarkets published an article 4:28 PM

The Cost to Treat Cholesterol Plummets, But Will It Last?

Thanks to growing use of generics, spending on cholesterol treatments is falling. However, that may change once PCSK9 drugs from Amgen (AMGN), Regeneron (REGN), and Pfizer (PFE) reach the market.

NL

Article

EBCapitalMarkets published an article 1:16 PM

Stunning Spending Growth Prediction for Hepatitis C

New drugs from Gilead (GILD), Johnson & Johnson (JNJ), Bristol-Myers (BMY), and AbbVie (ABBV) have Express Scripts (ESRX) forecasting spending on hepatitis C drugs will double this year.

NL

Article

EBCapitalMarkets published an article 9:58 AM

Warren Buffett Owns This Big Data Stock: Should You?

Verisk Analytics (VRSK), United Healthcare (UNH), and McKesson (MKC) are facing off with big data crunching solutions that could re-imagine healthcare markets.

Tue Apr 8

NL

Article

EBCapitalMarkets published an article 2:06 PM

Pharmacy Face-Off: Rite Aid, Walgreen, or CVS

With baby boomers aging and reform increasing the number of insured, pharmacy demand may be about to surge, but does that make Rite-Aid (RAD), Walgreen (WAG), or CVS (CVS) a better buy?

NL

Article

EBCapitalMarkets published an article 9:53 AM

Here's What's Behind Puma's Crash

Puma Biotech (PBYI) is working on a promising breast cancer drug, but its shares are dropping sharply. Here's what you need to know about neratinib and why Puma investors got nervous.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating < 20
Player Rank 61786 out of 75542
Score -205.66
Score Change Today -9.10
Accuracy 32.35%
Active Picks 34
Total Picks 34
Best Pick SAM (+20.02)
Worst Pick BJRI (-37.92)
Average Score per Pick -6.05
Charms Earned 6
Highest Rated Favorite No Favorites Selected
Go to TMFEBCapital’s CAPS page

Boards Stats & Trivia

Board Posts 0
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board N/A
Very First Post N/A
Percentage of Posts Rec'd 100.00 %
Show TMFEBCapital’s 10 Latest Posts